The Top 10 Generic Pharmaceutical Companies: Positioning, performance and SWOT analyses

The Top 10 Generic Pharmaceutical Companies: Positioning, performance and SWOT analyses
Table of Contents

The Top 10 Generic Pharmaceutical Companies

Executive Summary 14

Industry overview 14

Novartis (Sandoz) 15

Teva 16

Mylan 16

Ratiopharm 17

Apotex 18

Pfizer (Greenstone) 19

Sanofi-Aventis (Winthrop) 20

Watson 21

Bayer 22

Stada 22

Chapter 1 Introduction 26

What is this report about? 26

Methodology 26

Chapter 2 Industry overview 28

Summary 28

Introduction 29

Market overview 29

Global generics market: size and growth 29

Market overview for the US/5EU 30

The US 32

The UK 34

France 36

Germany 37

Spain 39

Italy 41

Top trends in the industry 43

Changing paradigms towards emerging markets 43

The generics manufacturing base is shifting to low cost hubs 45

Growing legislative support for 'follow-on biologics' 46

Increasing participation of branded Pharma companies in generics industry 47

Consolidation 49

Top ten generic companies 50

Global ranking 50

US/5EU consolidated 50

Therapeutic focus of the top 10 51

Key marketed products of the top 10 53

Geographic focus of the top 10 54

US ranking 54

EU ranking 55

Chapter 3 Novartis (Sandoz) 58

Summary 58

Business description 59

Geographic focus 60

Marketed products 61

Major therapeutic focus 62

Growth strategies 63

Focus on difficult-to-make and biosimilar generics 63

Acquisitions and divestments 64

SWOT analysis 65

Strengths 66

Size and leading generics position 66

Dynamic launches 66

Weaknesses 67

Development setbacks 67

Opportunities 67

Strong pipeline 67

Threats 68

Legal proceedings 68

Chapter 4 Teva 70

Summary 70

Business description 71

Geographic focus 72

Marketed products 73

Major therapeutic focus 74

Growth strategies 76

Acquisitions and divestments 76

SWOT analysis 77

Strengths 78

Leading generics market position 78

Global infrastructure 78

Weaknesses 79

Distribution model 79

Opportunities 79

Focus on hospitals and institutional channels 80

Threats 80

Failure to obtain market exclusivity in the US 80

Chapter 5 Mylan 84

Summary 84

Business description 85

Geographic focus 86

Marketed products 87

Major therapeutic focus 88

Growth strategies 89

Acquisitions and divestments 90

SWOT analysis 91

Strengths 91

Leading market position in Asia Pacific 91

Growth through strategic acquisitions 92

Weaknesses 92

Dependence on a few key products 92

Opportunities 93

Growing generics demand 93

Threats 93

Merck Generics litigations 93

Chapter 6 Ratiopharm 96

Summary 96

Business description 97

Geographic focus 97

Marketed products 99

Major therapeutic focus 99

Growth strategies 100

Focus on biosimilars 100

Acquisitions and divestments 101

SWOT analysis 102

Strengths 102

Leading position in Germany 102

Weaknesses 103

Dependence on European market 103

Opportunities 103

Biosimilar filgrastim 103

Launch of generic Plavix 103

Threats 104

Competition in German generics market 104

Chapter 7 Apotex 106

Summary 106

Business description 107

Geographic focus 107

Marketed products 108

Major therapeutic focus 109

Growth strategies 110

Strategic alliances 110

Investments in R&D 111

Acquisitions and divestments 111

SWOT analysis 112

Strengths 112

Strong R&D capabilities 112

Weaknesses 113

Lawsuits relating to patent infringement 113

Opportunities 113

Expanding global footprint beyond Canada and the US 113

Successful tender bid for critical healthcare needs in Africa 114

Threats 114

Extending market exclusivity period in Canada 114

Growing pseudo (authorized) generics market in Canada 114

Chapter 8 Pfizer (Greenstone) 118

Summary 118

Business description 119

Geographic focus 119

Marketed products 120

Major therapeutic focus 121

Growth strategies 122

Extending generics market share 122

Acquisitions and divestments 123

SWOT analysis 123

Strengths 123

Strong market position 123

Weaknesses 124

Geographic concentration in the US 124

Opportunities 124

Growth opportunities in emerging markets 124

Threats 125

Competition in the US generics market 125

Chapter 9 Sanofi-Aventis (Winthrop) 128

Summary 128

Business description 129

Geographic focus 129

Marketed products 130

Major therapeutic focus 131

Growth strategies 133

Regionalization strategy 133

Acquisitions and divestments 133

SWOT analysis 134

Strengths 134

Strong presence in emerging economies 134

Weaknesses 135

Lack of presence in the US 135

Opportunities 135

Biosimilar generics in the field of low molecular weight heparin 135

Threats 135

Low penetration of generics in France 135

Chapter 10 Watson 138

Summary 138

Business description 139

Geographic focus 139

Marketed products 140

Major therapeutic focus 140

Growth strategies 142

Growing offshore presence 142

Acquisitions and divestments 142

SWOT analysis 143

Strengths 143

Global centers of excellence 143

Weaknesses 144

Dependence on third-party manufacturers 144

Opportunities 144

Expansion in India 144

Threats 145

Loss of revenues from Ferrlecit 145

Chapter 11 Bayer 148

Summary 148

Business description 149

Geographic focus 149

Marketed products 150

Major therapeutic focus 151

Growth strategies 152

Building on government initiatives to promote generics 152

Acquisitions and divestments 152

SWOT analysis 153

Strengths 153

Strong R&D capabilities 153

Weaknesses 154

Lack of presence in the US and the UK 154

Opportunities 154

Focus on emerging economies 154

Threats 154

Regulatory pressure on generic pricing in Germany 154

Chapter 12 Stada 158

Summary 158

Business description 159

Geographic focus 159

Marketed products 161

Major therapeutic focus 162

Growth strategies 163

Cost optimization 163

Continuous portfolio expansion 163

Acquisitions and divestments 164

SWOT analysis 165

Strengths 165

Low-price cost structure of ALIUD Pharma 165

Strong local sales infrastructure 166

Weaknesses 166

Dependence on third-party suppliers and manufacturers 166

Opportunities 166

Launch of biosimilar Erythropoietin-zeta 166

Expanding footprint in Eastern Europe 167

Threats 167

Regulatory pressure on generics pricing in Germany 167

Chapter 13 Conclusion 170

Introduction 170

Generics outperforming the ethical pharmaceutical industry 170

Reassessing growth strategies 170

Generics competition within the biotech sector 171

Stripping-off the pricing advantage 171

Outlook 172

Chapter 14 Appendix 176

Glossary 176

Index 178

List of Figures

Figure 3.1: Global generics market size, 2004–2007 ($m) 30

Figure 3.2: Market position of the global top 10 generics companies, 2007 32

Figure 3.3: Generics drivers and resistors - the US 33

Figure 3.4: Generics drivers and resistors - the UK 35

Figure 3.5: Generics drivers and resistors - France 37

Figure 3.6: Generics drivers and resistors - Germany 38

Figure 3.7: Generics drivers and resistors - Spain 40

Figure 3.8: Generics drivers and resistors - Italy 42

Figure 3.9: Emerging markets generic sales, 2003–2007 ($m) 44

Figure 3.10: Pharmaceutical companies and their generic divisions 48

Figure 3.11: Top 10 generic companies global market share, 2007 50

Figure 3.12: Geographic focus of the top 10 in US/5EU, 2007 54

Figure 4.13: Novartis’ (Sandoz) geographic focus, 2006–2007 60

Figure 4.14: Novartis’ (Sandoz) therapeutic focus, 2007 63

Figure 4.15: Novartis (Sandoz) SWOT analysis 65

Figure 5.16: Teva’s geographic focus, 2006–2007 73

Figure 5.17: Teva’s therapeutic focus, 2007 75

Figure 5.18: Teva SWOT analysis 77

Figure 6.19: Mylan’s geographic focus, 2006–2007 87

Figure 6.20: Mylan’s therapeutic focus, 2007 89

Figure 6.21: Mylan SWOT analysis 91

Figure 7.22: Ratiopharm’s geographic focus, 2006–2007 98

Figure 7.23: Ratiopharm’s therapeutic focus, 2007 100

Figure 7.24: Ratiopharm SWOT analysis 102

Figure 8.25: Apotex’s geographic focus, 2006–2007 108

Figure 8.26: Apotex’s therapeutic focus, 2007 110

Figure 8.27: Apotex SWOT analysis 112

Figure 9.28: Pfizer’s (Greenstone) geographic focus, 2006–2007 120

Figure 9.29: Pfizer’s (Greenstone) therapeutic focus, 2007 122

Figure 9.30: Pfizer (Greenstone) SWOT analysis 123

Figure 10.31: Sanofi-Aventis’ (Winthrop) geographic focus, 2006–2007 130

Figure 10.32: Sanofi-Aventis’ (Winthrop) therapeutic focus, 2007 132

Figure 10.33: Sanofi-Aventis (Winthrop) SWOT analysis 134

Figure 11.34: Watson’s therapeutic focus, 2007 141

Figure 11.35: Watson SWOT analysis 143

Figure 12.36: Bayer’s geographic focus, 2006–2007 150

Figure 12.37: Bayer’s therapeutic focus, 2007 152

Figure 12.38: Bayer SWOT analysis 153

Figure 13.39: Stada’s geographic focus, 2006–2007 160

Figure 13.40: Stada’s therapeutic focus, 2007 162

Figure 13.41: Stada SWOT analysis 165

Figure 14.42: Comparative analysis of top 10 generic companies 172

List of Tables

Table 3.1: Total generic sales in the US/5EU, 2003–2007 ($m) 31

Table 3.2: Generic sales by volume in the US/5EU, 2003–2007 (Standard units m) 31

Table 3.3: Biologics going off patent in the US, 2008–2011 47

Table 3.4: Top 10 generic companies’ sales in the US/5EU, 2003–2007 ($m) 51

Table 3.5: Largest therapy areas for generics for the top 10, 2007 ($m) 52

Table 3.6: Market share by therapy area in the US/5EU generics market, 2006–2007 52

Table 3.7: Top 10 generics by sales value in the US/5EU, 2007 ($m) 53

Table 3.8: Top 10 generic companies in the US, 2003–2007 ($m) 55

Table 3.9: Top 10 generics companies in 5EU, 2003–2007 ($m) 56

Table 4.10: Novartis (Sandoz) snapshot 59

Table 4.11: Novartis’ (Sandoz) top 10 marketed products sales, 2006–2007 ($m) 61

Table 5.12: Teva snapshot 71

Table 5.13: Teva's top 10 marketed products sales, 2006–2007 ($m) 74

Table 6.14: Mylan snapshot 85

Table 6.15: Mylan's top 10 marketed products sales, 2006–2007 ($m) 88

Table 7.16: Ratiopharm snapshot 97

Table 7.17: Ratiopharm's top 10 marketed products sales, 2006–2007 ($m) 99

Table 8.18: Apotex snapshot 107

Table 8.19: Apotex' top 10 marketed products sales, 2006–2007 ($m) 109

Table 9.20: Pfizer (Greenstone) snapshot 119

Table 9.21: Pfizer’s (Greenstone) top 10 marketed products sales, 2006–2007 ($m) 121

Table 10.22: Sanofi-Aventis (Winthrop) snapshot 129

Table 10.23: Sanofi-Aventis’ (Winthrop) top 10 marketed products sales, 2006–2007 ($m) 131

Table 11.24: Watson snapshot 139

Table 11.25: Watson's top 10 marketed products sales, 2006–2007 ($m) 140

Table 12.26: Bayer snapshot 149

Table 12.27: Bayer's top 10 marketed products sales, 2006–2007 ($m) 151

Table 13.28: Stada snapshot 159

Table 13.29: Stada’s top 10 marketed products sales, 2006–2007 ($m) 161

</p>>!!